Unibest
← Back to patent-cliff list

Drugs Losing Exclusivity in 2031 & Key Intermediates

9 · Expiring drugs8 · Routes recorded8 · With on-sale intermediates

9 drugs expire in 2031 (public sources), 8 with recorded synthesis routes; key intermediates of 8 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.

DrugTierExpiryIndicationsRoutesCAS countAvailable
Osimertinib MesylateA · Act now2031Non-small cell lung cancer429Available ×29
VibegronC · Watch2031Overactive bladder, Urinary incontinence222Available ×22
RelugolixC · Watch2031Prostate cancer, Leiomyoma112Available ×12
DarolutamideB · Position early2031Hormone-sensitive prostate cancer, Castration-sensitive prostate cancer, Prostate cancer19Available ×9
Lumateperone tosylateC · Watch2031Major depressive disorder, Depression, Schizophrenia19Available ×9
PralsetinibC · Watch2031Non-small cell lung cancer, Thyroid cancer, Medullary thyroid cancer741Available ×4
ZanubrutinibA · Act now2031Waldenström macroglobulinaemia, Chronic lymphocytic leukaemia, Follicular lymphoma112Available ×2
LusutrombopagC · Watch2031Thrombocytopenia112Available ×1
SemaglutideA · Act now2031Overweight, Obesity, Type 2 diabetes---

Frequently asked questions

Which drugs lose exclusivity in 2031?

9 drugs expire in 2031 per public sources: Osimertinib Mesylate, Zanubrutinib, Pralsetinib, Lumateperone tosylate, Darolutamide, Relugolix, etc.

When should we start sourcing intermediates for 2031 launches?

Generic developers typically secure development-scale supply 2–3 years before expiry. 8 of the 9 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.

Are route and CAS data verified?

All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.

Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-29